Case Analysis of Hypokalemia Induced by Irbesartan-Hydrochlorothiazide: A Case Study

Abstract

Irbesartan-hydrochlorothiazide is a commonly used antihypertensive drug, but potential adverse reactions such as hypokalemia should not be overlooked. This study analyzes a case of hypokalemia induced by irbesartan-hydrochlorothiazide, exploring the drug’s association with hypokalemia and clinical treatment strategies. The patient experienced symptoms of muscle weakness and palpitations after taking irbesartan-hydrochlorothiazide and was diagnosed with hypokalemia through laboratory tests. Reviewing the patient’s medication history and disease progression, it was hypothesized that the drug’s potassium-wasting effect was the direct cause of the hypokalemia. After discontinuing the medication and initiating potassium supplementation, the patient’s potassium levels returned to normal, and symptoms significantly improved, further confirming the link between hypokalemia and the medication. This case suggests that clinicians should consider the risk of hypokalemia when treating hypertension, especially in patients with chronic kidney disease, the elderly, or those at risk for electrolyte disturbances. For patients who have already developed hypokalemia, potassium supplementation and adjustment of the treatment regimen are recommended to prevent further deterioration. Timely discontinuation of potential causative drugs is also advised. In summary, ensuring medication safety and preventing potential complications has significant clinical importance in recognizing and managing hypokalemia induced by irbesartan-hydrochlorothiazide. Future research should focus on optimizing treatment protocols and developing more effective strategies for preventing and managing related adverse reactions to improve patient quality of life.